**Supplementary table 2:** Summary of studies reporting on CPR performed on IHCA in patients diagnosed with COVID-19

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Hayek 2020 (13)** | **Bhatla 2020 (18)** | **Miles 2020 (19)** | **Shah 2020 (14)** | **Shao 2020 (15)** | **Sheth 2020 (20)** | **Thapa 2020 (21)** | **Yuriditsky 2020 (22)** | **Total** |
| Location of study | Nationwide, USA | Philadelphia, USA | New York, USA | Georgia, USA | Hubei (Wuhan), China | New York, USA | Michigan, USA | New York, USA |  |
| Study period | 4 March 2020 to 1 June 2020 | 6 March 2020 to 19 May 2020 | 1 March 2020 to 15 May 2020 | 2 March 2020 to 26 August 2020 | 15 January 2020 to 25 February 2020 | 1 March 2020 to 18 May 2020 | 15 March 2020 to 3 April 2020 | 25 March 2020 to 10 May 2020 |
| Study quality by NOS | Good | Fair | Fair | Fair | Good | Fair | Fair | Fair |
| **IHCA Location in hospital** | | | | | | | | | |
| * In ICU | 400  (100.0, 99.1-100.0) | 9  (100, 66.4-100) | 29  (29.3, 20.6-39.3) | 53  (84.1, 72.7-92.1) | 23  (16.9, 11.0-24.3) | 24  (77.4, 58.9-90.4) | 0 | 46 (83.6, 71.2-92.2) | 584/847  (68.9%) |
| * Non-ICU# | 0 | 0 | 70 | 10 | 113 | 7 | 0 | 9 | 224 |
| * Not specified | 0 | 0 | 0 | 0 | 0 | 0 | 54 | 0 | 54 |
| * Total Sample size, N | 400 | 9 | 99 | 63 | 136 | 31 | 54 | 55 | 847 |
| Incidence of IHCA (Where CPR was performed) | 400/5019  (8.0, 7.2-8.8)\* | 9/79  (11.4, 5.3-20.5)\* | NR | 63/1094  (5.8, 4.5-7.3)\*\* | 136/761  (17.9, 15.2-20.8)\*\*\* | NR | 54/1309  (4.1, 3.1-5.3)\*\* | 55/3675 (1.5, 1.1-1.9) | 717/11937  (6.0%) |
| Male, N (%) | 266  (66.5, 61.6-71.1) | NR | 66  (66.7, 56.5-75.8) | 31  (49.2, 36.4-62.1) | 90  (66.2, 57.6-74.1) | 22  (71.0, 52.0-85.8) | 33  (61.1, 46.9-74.1) | 48  (87.3, 75.5-94.7) | 556/847  (65.6%) |
| Age, Mean (SD) | 61.0 (14.0) | 53.8 (16.6) | 65.2 (14.7) | 66.3 (11.4) | 69 (NR) | 67.3 (14.8) | 59.8 (13.7) | 68.6 (12.2) | 63.7 (14.1) |
| **Comorbidities** | | | | | | | | | |
| * Obesity | 102  (25.5, 21.3-30.1) | 2  (22.2, 2.8-60.0) | NR | 45  (71.4, 58.7-82.1) | NR | NR | NR | NR | 149/472  (31.6%) |
| * Hypertension | 253  (63.3, 58.3-68.0) | NR | NR | 56  (88.9, 78.4-95.4) | 41  (30.1, 22.6-38.6) | NR | 42  (77.8, 64.4-88.0) | 39  (70.9, 57.1-82.4) | 431/708  (60.9%) |
| * Diabetes mellitus | 201  (50.3, 45.2-55.3) | 1  (11.1, 0.3-48.2) | 39  (39.4, 29.7-49.7) | 40  (63.5, 50.4-75.3) | 27  (19.9, 13.5-27.6) | 13  (41.9, 24.5-60.9) | 50  (92.6, 82.1-97.9) | 17  (30.9, 19.1-44.8) | 388/847  (45.8%) |
| * Congestive heart disease | 114  (28.5, 24.1-33.2) | 1  (11.1, 0.3-48.2) | 9  (9.1, 4.2-16.6) | 10  (15.9, 7.9-27.3) | 15  (11.0, 6.3-17.5) | 17  (54.8, 36.0-72.7) | NR | 8  (14.5, 6.5-26.7) | 174/793  (21.9%) |
| * Cancer | 17  (4.3, 2.5-6.7) | NR | 10  (10.1, 5.0-17.8) | 6  (9.5, 3.6-19.6) | 10  (7.4, 3.6-13.1) | 5  (16.1, 5.5-33.7) | NR | NR | 48/729  (6.6%) |
| * Asthma or COPD | 31  (7.8, 5.3-10.8) | 1  (11.1, 0.3-48.2) | NR | 9  (14.3, 6.7-25.4) | 5  (3.7, 1.2-8.4) | NR | NR | NR | 46/608  (7.6%) |
| * Chronic kidney disease | 84  (21.0, 17.1-25.3) | NR | 34  (34.3, 25.1-44.6) | 17  (27.0, 16.6-39.7) | 3  (2.2, 0.5-6.3) | 9  (29.0, 14.2-48.0) | NR | 23  (41.8, 28.7-55.9) | 170/784  (21.7%) |
| * Cerebrovascular disease | NR | 1  (11.1, 0.3-48.2) | 0  (0.0, 0.0-3.7) | 11  (17.5, 9.1-29.1) | 5  (3.7, 1.2-8.4) | NR | NR | NR | 17/307  (5.5%) |
| **Initial rhythm** | | | | | | | | | |
| * Ventricular arrhythmia | 48  (12.0, 9.0-15.6) | 1  (11.1, 0.3-48.2) | 3/93  (3.2, 0.7-9.1) | 5  (7.9, 2.7-17.6) | 8  (5.9, 2.6-11.3) | 4  (12.9, 3.6-29.8) | 2  (3.7, 0.5-12.7) | 6  (10.9, 4.1-22.2) | 77/841  (9.2%) |
| * Pulseless electrical activity | 199  (49.8, 44.7-54.8) | 6  (66.7, 29.9-92.5) | 49/93  (52.7, 42.1-63.1) | 37  (58.7, 45.6-71.0) | 6  (4.4, 1.6-9.4) | 18  (58.1, 39.1-75.4) | 44  (81.5, 68.6-90.7) | 41  (74.5, 61.0-85.3) | 400/841  (47.6%) |
| * Asystole | 95  (23.8. 19.7-28.2) | 2  (22.2, 2.8-60.0) | 41/93  (44.1, 33.8-54.8) | 21  (33.3, 22.0-46.3) | 122  (89.7, 83.3-94.3) | 9  (29.0, 14.2-48.0) | 8  (14.8, 6.6-27.1) | 8  (14.5, 6.5-26.7) | 306/841  (36.4%) |
| **ROSC** | **135**  **(33.8, 29.1-38.6)** | **6  (66.7, 29.9-92.5)** | **35**  **(35.4, 26.0-45.6)** | **18**  **(28.6, 17.9-41.3)** | **18  (13.2, 8.0-20.1)** | **20  (64.5, 45.4-80.8)** | **29**  **(53.7, 39.6-67.4)** | **21**  **(38.2, 25.4-52.3)** | **282/847**  **(33.3%)** |
| **In-Hospital Mortality** | **352 (88.0%)** | **4 (44.4%)^** | **97 (98.0%)** | **63 (100%)** | **132 (97.1%)** | **31 (100%)** | **54 (100%)** | **44 (80.0%)** | **777/847 (91.7%)** |
| Data published as N (%, 95% CI). NOS: Newcastle Ottawa Scale; USA: United States of America; SD: Standard deviation; N: Number; NR: Not reported; ICU: Intensive Care Unit; COPD: Chronic obstructive lung disease; ROSC: Return of spontaneous circulation; Ventricular arrhythmia - Ventricular fibrillation, ventricular tachycardia or torsades de pointes.  # IHCA that happened in emergency department and all wards (excluding ICU).  \* Among COVID-19 patients admitted to the ICU.  \*\* Among all hospitalized COVID-19 patients within the study period  \*\*\* Among severe COVID-19 patients  ^ Four patients died, with three still remaining hospitalized at study conclusion\ | | | | | | | | | |